Pharmaceutical kit for use in the treatment of colon and colorectal cancer

The present invention describes therapies for the effective treatment of colon and colorectal carcinomas. The present invention relates to a pharmaceutical kit comprising ibrutinib and fluorouracil, for the treatment of colon and colorectal carcinomas also in the case in which such carcinomas are drug resistant and therefore allows to overcome cancer drug resistance.
Field of the invention

The present invention describes novel therapies for the effective treatment of drug resistant colon and colorectal carcinomas.

State of the art

Apoptosis is a common mode of eukaryotic cell death that is triggered by an inducible cascade of biochemical events leading to the activation of DNA cleavage. Most chemotherapeutic agents exert their anticancer activity by inducing apoptosis. Cell resistance to apoptosis is therefore a major factor which limits the effective anticancer therapy.

Bruton's tyrosine kinase (BTK), a member of the Tec family of cytoplasmic tyrosine kinases, is intimately involved in multiple signal-transduction pathways regulating survival, activation, proliferation, and differentiation of B-lineage lymphoid cells.

BTK has been reported responsible for triggering radiation-induced apoptosis of lymphoma B cells, and its kinase domain is indispensable for the apoptotic response. BTK and other members of the Tec kinase family are expressed in various tissues, and recent studies suggest that since BTK is an apoptosis modulating molecule, alteration of its function could be cause of various types of cancer.

WO2008110624 describes the identification and isolation of a novel isoform of the BTK protein, having a molecular weight of 65-68 kDa. The novel BTK protein, also identified as p65BTK, is shorter than the BTK identified in B cells, and its mRNA has a different first exon.

p65BTK was identified in epithelial carcinoma cell lines such as breast, ovary, lung and colon. In particular p65BTK was seen to have a high expression in epithelial carcinoma cells which were proved resistant to chemotherapeutic agents.

In WO2008110624 it is shown that resistance to chemotherapeutic drugs can be reverted by inhibiting p65BTK expression, indicating the achievement of a first step to cancer treatment.

WO2008039218 describes compounds that inhibit BTK, by forming a covalent bond with a cysteine residue of BTK. One of the compounds described is 1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (Compound 4).

WO2010009342 describes BTK inhibitor compounds such as 1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and their use in the treatment of tumors. Among the therapeutic uses of the inhibitor compounds, WO2010009342 indicates the inhibition of lymphoma tumor cell growth, the inhibition of collagen-induced arthritis, the inhibition of lupus and of mast cell degeneration.

WO2010009342 also indicates the administration of a BTK inhibitor (Compound 1) to a mouse model for colon cancer. A colon cancer xenograft is implanted under the skin of a mouse and the size of the tumor xenograft is monitored upon Compound 1 administration.

Many cancers develop resistance to chemotherapeutic drugs, a major factor in the failure of many forms of chemotherapy. Drug resistance affects patients with a variety of blood cancers and solid tumors, including breast, ovarian, lung, and lower gastrointestinal tract cancers.

The need and importance is increasingly felt for novel therapies for the effective treatment of colon and colorectal carcinomas, and drug-resistant colon and colorectal carcinomas once the resistance to chemotherapeutic drugs is acknowledged.

It is therefore object of the present invention the effective treatment of colon and colorectal carcinomas, both drug-sensitive and drug-resistant.

Summary of the invention

The present inventors have surprisingly found that if you administer ibrutinib and fluorouracil to colon carcinomas and to colorectal carcinomas, said carcinomas are treated.

Therefore the present invention concerns a pharmaceutical kit for use in the treatment of colon and colorectal carcinomas.

In particular the invention relates to a pharmaceutical kit for simultaneous, sequential and separate use of an effective dose of ibrutinib and an effective dose of fluorouracil, in the treatment of colon and colorectal carcinomas, both drug-sensitive and drug-resistant.

The invention further relates to a method for the treatment of resistant colon and colorectal carcinomas, comprising the administration of and effective dose of ibrutinib and of an effective dose of fluorouracil.

As will be further described in the detailed description of the invention, the pharmaceutical kit of the present invention has the advantages of being specific for the treatment of colon and colorectal carcinomas, both drug-sensitive and drug-resistant.

Brief description of the drawings

The characteristics and advantages of the present invention will be apparent from the detailed description reported below, from the Examples given for illustrative and nonlimiting purposes, and from the annexed Figures 1-10, wherein:

Figure 1 shows the effect of different concentrations of ibrutinib on cell proliferation as illustrated in particular in the growth curves (short term assays) as described in Example 1:

Figure 1 a: dose-response curve of HCT116
cells grown in presence of increasing concentrations of irbutinib (from 0 to 10 \( \mu \)M), for 72 hours; 5000 cells/well were seeded in triplicates and cell number was assessed each 24 hs by use of CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega).

Figure 1b: dose-response curve of HCT116p53KO cells grown in presence of increasing concentrations of irbutinib (from 0 to 10 \( \mu \)M) for 72 hours; 5000 cells/well were seeded in triplicates and cell number was assessed each 24 hs by use of CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega).

Figure 1c: dose-response curve of DLD-1 cells grown in presence of increasing concentrations of irbutinib (from 0 to 10 \( \mu \)M) for 72 hours; 5000 cells/well were seeded in triplicates and cell number was assessed each 24 hs by use of CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega).

Figure 1d: dose-response curve of SW480 cells grown in presence of increasing concentrations of irbutinib (from 0 to 10 \( \mu \)M) for 72 hours; 5000 cells/well were seeded in triplicates and cell number was assessed each 24 hs by use of CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega).

Figure 2 shows the effect of different concentrations of irbutinib (from 0 to 20 \( \mu \)M) on the proliferation of three colon carcinoma cell lines which are resistant to 5FU (HCT116p53KO, SW480 and DLD-1) and on the sensitive HCT116 cell line as illustrated in the colony assay experiment (long term assay) described in Example 2.

Figure 3 shows the effect of different concentrations of irbutinib (from 0 to 20 \( \mu \)M) and of irbutinib (from 0 to 20 \( \mu \)M) + 5FU (200 \( \mu \)M) on viability of HCT116 and HCT116p53KO colon carcinoma cell lines as described in Example 3.

Figure 4 shows the results of the combined treatment of irbutinib and three different anti-tumour ("targeted" drugs for the inhibition of EGFR (cetuximab, panitumumab) and of VEGF (bevacizumab) as described in Example 4.

Figure 5a shows the growth curve of tumors derived from HCT116p53KO cells xenografted in CD1 mice after treatment with irbutinib (25mpk), 5FU (60mpk) and irbutinib (25mpk) + 5FU (60mpk), compared to the control (vehicle) as described in Example 5.

Figure 5b shows the range of tumor volumes measured at the end of the treatment of the mice xenografted with HCT116p53KO cells with irbutinib (25mpk), 5FU (60mpk), irbutinib (25mpk) + 5FU (60mpk), and vehicle alone (ctrl). In the box plot graph of Figure 5b, the bold line indicates the median of the values, the box indicates the first and third quartile.

The maximum and minimum values for each group are also reported as described in Example 5.

Figure 6a shows the growth curve of tumors derived from HCT116p53KO cells xenografted in CD1 mice after treatment with irbutinib (50mpk), 5FU (60mpk) and irbutinib (50mpk) + 5FU (60mpk), compared to the control (vehicle) as described in Example 5.

Figure 6b shows the range of tumor volumes measured at the end of the treatment of the mice xenografted with HCT116p53KO cells with irbutinib (50mpk), 5FU (60mpk), irbutinib (50mpk) + 5FU (60mpk), and vehicle alone (ctrl). In the box plot graph of Figure 6b, the bold line indicates the median of the values, the box indicates the first and third quartile. The maximum and minimum values for each group are also reported as described in Example 5.

Figure 7a shows the proliferative index, evaluated as the percentage of Ki67-positive cells, of the tumoral tissues excised from the mice at the end of the treatment at the end of the treatment with vehicle alone (Ctrl), 5FU (60mpk), irbutinib 25 mpk, 5FU (60mpk) + irbutinib 25mpk. Data are expressed as mean ± SEM.

Figure 7b shows the proliferative index, evaluated as the percentage of Ki67-positive cells, of the tumoral tissues excised from the mice at the end of the treatment at the end of the treatment with vehicle alone (Ctrl), 5FU (60mpk), irbutinib 50 mpk, 5FU (60mpk) + irbutinib 50mpk. Data are expressed as mean ± SEM.

Figure 7c shows the percentage of necrotic area measured in the tumoral tissues excised from the mice at the end of the treatment with vehicle alone (Ctrl), 5FU (60mpk), irbutinib 25 mpk, 5FU (60mpk) + irbutinib 25mpk, 5FU (60mpk) + irbutinib 50mpk. Data are expressed as mean ± SEM as described in Example 5.

Figure 8a shows the growth curve of tumors derived from HCT116 xenografted in CD1 mice after treatment with irbutinib (25mpk), 5FU (60mpk) and irbutinib (25mpk) + 5FU (60mpk), compared to the control (vehicle). The proliferative index of the tumoral tissues excised from the mice at the end of the treatment, evaluated as the percentage of Ki67-positive cells, is shown in Figure 8b.

Data are expressed as mean ± SEM as described in Example 5.

Figure 9a shows the growth curve of tumors derived from HCT116 xenografted in CD1 mice after treatment with irbutinib (50mpk), 5FU (60mpk) and irbutinib (50mpk) + 5FU (60mpk), compared to the control (vehicle).

Figure 9b shows the proliferative index of the tumoral tissues excised from the mice at the end of the treatment evaluated as the percentage of Ki67-positive cells. Data is expressed as mean ± SEM as described in Example 5.
Figure 10 shows the effect of combining 5FU and ibrutinib treatments in drug-resistant (HCT116p53KO) and -sensitive (HCT116) colon carcinoma cells. In Figure 10a are shown representative photographs of HCT116p53KO cells taken at 72 hours of incubation in presence of 200 μM 5FU, 20 μM ibrutinib, 200 μM 5FU + 20 μM ibrutinib. Figure 10b shows representative photographs of HCT116 cells taken at 72 hours of incubation in presence of 200 μM 5FU, 10 μM 5FU, 50 μM ibrutinib, 10 μM 5FU + 50 μM ibrutinib as described in Example 6.

Detailed description of the invention

[0019] The present invention concerns a pharmaceutical kit for simultaneous, sequential and separate use of an effective dose of ibrutinib and an effective dose of fluorouracil, in the treatment of colon and colorectal carcinomas.

[0020] The inventors have surprisingly found that the treatment of colon or colorectal carcinomas by the simultaneous or sequential administration of ibrutinib and fluorouracil results in a synergic antitumoral effect compared to the administration of either of the components individually. This surprising synergic antitumoral effect has been seen also in drug-resistant colon and colorectal carcinomas, which are those cancers which develop resistance to chemotherapy drugs. The pharmaceutical kit according to the present invention allows to overcome cancer drug resistance due to the many mechanisms of tumor cell evolution and adaptation.

[0021] A further surprising advantage of the present invention relates to the fact that the inventors have found that in the treatment of colon or colorectal carcinomas by the simultaneous or sequential administration of ibrutinib and fluorouracil, a smaller or lower amount of the chemotherapeutic drug can be used and is efficacious, in comparison to the amount of chemotherapeutic drug which is used in the treatment of the same carcinomas.

[0022] The amount of chemotherapeutic drug, fluorouracil, can be reduced in a range from 5% to 80%, preferably in a range from 10% to 60%, more preferably from 20% to 40%, still more preferably from 25% to 35%.

[0023] The present invention further concerns a pharmaceutical kit for simultaneous, sequential and separate use of an effective dose of ibrutinib and an effective dose of fluorouracil, in the treatment of drug-resistant colon and colorectal carcinomas.

[0024] In the present invention, by Fluorouracil or 5-FU is intended an antimetabolite drug used in the treatment of cancer, which acts through the irreversible inhibition of thymidylate synthase. 5-FU induces cell cycle arrest and apoptosis by inhibiting the cell's ability to synthesize DNA. 5-FU has the following IUPAC name: 5-fluoro-1H,3H-pyrimidine-2,4-dione, and CAS number: 51-21-8.

[0025] In the present invention, by ibrutinib or ibr is intended a compound of formula

![Chemical Structure](image)

with the CAS identifier number: 936563-96-1, and chemical IUPAC name: 1-[(3R)-3-[4-amino-3-(4-phenoxypyrenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one.

[0026] Ibrutinib has been used in preclinical studies to for the treatment of chronic lymphocytic leukemia (CLL), and has been shown to promote apoptosis, inhibit proliferation, and also prevent CLL cells from responding to survival stimuli provided by the microenvironment. Ibrutinib is a selective and irreversible inhibitor of the enzyme Bruton tyrosine kinase (Btk), that forms a covalent bond with a cysteine residue on Btk.

[0027] Preclinical studies suggest that the treatment with ibrutinib has a safer toxicological profile, thus a benefit to cancer patients who usually experience the adverse side effects of chemotherapy such as fatigue, loss of appetite, nausea or vomiting.

[0028] In a second embodiment the pharmaceutical kit of the present invention surprisingly allows the treatment of drug-resistant cancer cells in a way that not only shows a synergic antitumoral effect of ibrutinib and fluorouracil, but also allow the use of lower amounts of fluorouracil, and thus a lower effective dose of the chemotherapy drug, thus avoiding the undesirable and often harmful side-effects that these drugs have.

[0029] A further aspect of the present invention is a pharmaceutical kit for simultaneous, sequential and separate use of an effective dose of ibrutinib and an effective dose of fluorouracil, wherein the ibrutinib is in the form of a pharmaceutically acceptable salt. In a further aspect, the invention provides a pharmaceutical kit comprising an effective dose of ibrutinib and an effective dose of fluorouracil, wherein the effective dose of ibrutinib and the effective dose of 5-fluorouracil are formulated as a pharmaceutical form selected from oral form, parenteral form and rectal form.

[0030] Depending on the method/route of administration, dosage forms can be of several types. These include many kinds of liquid, solid, and semisolid dosage forms. Common dosage forms include pill, tablet, or capsule, drink or syrup. The route of administration (ROA) for drug delivery is dependent on the dosage form of the substance.
Various dosage forms may exist for a single particular drug, since different medical conditions can warrant different routes of administration.

Routes of administration can be inhalational, buccal (oral), sublingual, nasal, suppository and parenteral.

In a still further aspect, the invention provides a pharmaceutical kit comprising an effective dose of irbitinib and an effective dose of fluorouracil, wherein the pharmaceutical form is an oral form, preferably a tablet.

Furthermore, the invention relates to a pharmaceutical kit for simultaneous, sequential and separate use of an effective dose of irbitinib and an effective dose of fluorouracil, wherein the pharmaceutical form comprises at least one pharmaceutical acceptable excipient.

An excipient is a pharmacologically inactive substance formulated with the active ingredient, commonly used to bulk up formulations that contain potent active ingredients (often referred to as “bulking agents,” “fillers,” or “diluents”), to allow convenient and accurate dispensation of a drug substance when producing a dosage form. They also can serve various therapeutic-enhancing purposes, such as facilitating drug absorption or solubility, or other pharmacokinetic considerations.

The selection of appropriate excipients also depends upon the route of administration and the dosage form, as well as the active ingredient and other factors.

In a preferred embodiment, the invention provides a pharmaceutical kit comprising an effective dose of irbitinib and an effective dose of fluorouracil, wherein the effective dose of irbitinib is in the range of from 1 mg/day to 2000 mg/day (derived from ClinicalTrials.gov; Study Identifiers: NCT01804686, NCT01589302, NCT01855750, NCT01744691, NCT01105247, NCT00849654) and wherein the effective dose of fluorouracil is in the range of from 400 mg/m² to 600 mg/m² (derived from the NCI page for colon cancer treatment for health professionals: http://www.cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional/page6).

In a more preferred embodiment the invention provides a pharmaceutical kit wherein the effective dose of irbitinib is in the range of from 10 mg/day to 1100 mg/day.

In a more preferred embodiment the invention provides a pharmaceutical kit wherein the effective dose of irbitinib is in the range of from 20 mg/day to 950 mg/day.

In a still more preferred embodiment, the invention provides a pharmaceutical kit comprising an effective dose of irbitinib and an effective dose of fluorouracil, wherein the effective dose of irbitinib is in the range of from 25 mg/day to 840 mg/day.

In a preferred embodiment the invention provides a pharmaceutical kit wherein the effective dose of fluorouracil is in the range of from 450 mg/m² to 550 mg/m².

In a still preferred embodiment the invention provides a pharmaceutical kit wherein the effective dose of fluorouracil is lower, preferably in a range from 150 mg/m² to 400 mg/m².

In a further aspect of the present invention the pharmaceutical kit comprises at least one container comprising the effective dose of irbitinib and at least one container comprising the effective dose of fluorouracil, and an instruction leaflet.

In a still further aspect of the present invention the use of an effective dose of irbitinib and an effective dose of fluorouracil, in the treatment of colon and colorectal carcinomas.

The use according to the present invention advantageously allows for the treatment of colon and colorectal carcinomas, wherein the colon and colorectal carcinomas are drug-resistant.

The invention further relates to a method for the treatment of colon and colorectal carcinomas, or delaying the recurrence of colon and colorectal carcinomas, comprising the administration of and effective dose of irbitinib and of an effective dose of fluorouracil.

The method according to the present invention advantageously allows for the treatment of colon and colorectal carcinomas, wherein the colon and colorectal carcinomas are drug-resistant.

In a first embodiment the method of treatment of a colon or colorectal cancer according to the present invention provides first administering to a patient an effective dose of irbitinib and sequentially an effective dose of fluorouracil.

In accordance with the present invention the effective doses of irbitinib and of fluorouracil can be provided in liquid, solid, and semisolid dosage forms depending on the routes of administration as indicated above.

The amount of irbitinib and of the fluorouracil in the unit dosage form is determined by the dosage to be used on a patient in the methods of the present invention.

In a second embodiment the method comprises administering to a colon or colorectal cancer patient the effective doses of irbitinib and of fluorouracil simultaneously.

In a further embodiment according to the present invention the effective doses of irbitinib and of fluorouracil can be administered separately.

Examples

Example 1. In vitro cell proliferation assays

The in vitro proliferation of HCT116p53KO, SW480 and DLD-1 cells, three colon carcinoma cell lines, which are resistant to 5FU treatment, and the HCT116 cell line, which is sensitive to 5FU treatment, were grown and assayed up to 72h after seeding, in the presence of different concentrations of irbitinib ranging from 0 to 10 μM.

As can be seen from the graphs of Figure 1,
these short term assays indicate that irbutinib does not alter the capacity of the cells to proliferate, even at a concentration of 10 μM.

Example 2. In vitro colony assays

[0055] The HCT116p53KO, SW480, DLD-1 cells and HCT116 cell lines were seeded at low density and grown for 10-12 days in the presence of different concentrations of irbutinib ranging from 0 to 20 μM.

[0056] As can be seen from the colony forming assays shown in Figure 2, these long term assays indicate that even in the long term, treatment with irbutinib does not affect clonogenic and proliferative capabilities up to a concentration of 1 μM. A concentration of 10 μM irbutinib decreases the number and the size of the colonies indicating that it affects both clonogenicity and proliferation, which are eventually inhibited at a concentration of 20 μM.

Example 3. Effect of irbutinib and fluorouracil treatment on cell viability

[0057] HCT116p53KO and HCT116 cell lines were grown in vitro for 72h in different concentrations of irbutinib (from 0 to 20 μM) and of irbutinib (from 0 to 20 μM) + 5FU (200 μM) and their viability was evaluated at the end of the incubation using the calcein assay (a non fluorescent dye that becomes fluorescent upon cleavage by lysosomal esterases, active only in living cells).

[0058] As can be seen from the graphs reported in Figure 3, concomitant administration of 200 μM 5FU (and irbutinib re-sensitize resistant HCT116p53KO cells to the cytotoxic effect of 5FU starting from the concentration of 100nM, to achieve a maximal effect at 20 μM. In contrast, the addition of irbutinib to 5FU in cell cultures of HCT116 (sensitive) has no additive effect on the response to chemotherapy.

Example 4. Effect of irbutinib on the response to targeted therapy

[0059] HCT116p53KO and HCT116 cell lines were grown in vitro and subjected to the combined treatment of irbutinib and three different monoclonal antibodies currently used in anti-cancer therapy for targeting EGFR (ce-tuximab, panitumumab) and VEGF (bevacizumab), both in short term (upper panel) and in long term (lower panel) experiments

[0060] In the upper part of Figure 4 the graph shows that the combined treatment with 20 μM irbutinib and these "targeted" drugs does not revert the resistance of HCT116p53KO cells, as assessed by Trypan blue staining 72h after the combined treatment. As shown in the lower panel, also the continuous exposure for 10-12 days to the combined treatment does not re-sensitize resistant cells to targeted therapy.

Example 5. In vivo treatment with irbutinib and fluorouracil

[0061] Tumors were established by injecting s.c. 1 x10⁶ cells (in 100 μL of a 50% PBS and 50% Matrigel solution), HCT116p53KO cells into the left flanks and HCT116 into the right flanks, of 5 to 7 weeks old female CD-1 nude mice. When HCT116p53KO tumors reached the average volume of 100 mm³ (day 8 postengraftment), animals were randomized and given vehicle, 5FU [via intraperitoneal (i.p.) injection, 60 mg/kg, twice a week], irbutinib [via oral gavage, 25 mg/kg (mpk) or 50 mpk once for 5 days a week], or a combination thereof. 5FU treatment started at day 9 post-engraftment, whereas irbutinib treatment started at day 8 post-engraftment. Control mice received i.p. injections of vehicle (0.9% NaCl solution) with the same schedule of the other groups. Tumors were measured with caliper once a week. Statistical significance was determined with a Kruskal-Wallis non parametric test (normal distribution not assumable), followed by Neményi-Damicco-Wolfe-Dunn test for multiple pairwise comparisons between groups. In all cases, a P value < 0.05 was considered as significant

[0062] As can be seen from the graph reported in Figure 5a, after 28 days of treatment the average volume of the tumor masses formed by xenografted drug-resistant HCT116p53KO amounts to ~955mm³ for the group of untreated mice (vehicle), to ~760mm³ for the group treated with irbutinib (25mpk) alone, to ~530mm³ for the group treated with 5FU alone and to ~315mm³ for the group treated with the combination of irbutinib and 5FU. As illustrated in Figure 5b statistical analysis shows that the reduction in the tumor volume is not significant when comparing the group of mice treated with 5FU alone vs the untreated group but it become significant when comparing the group of mice treated with 5FU+irbutinib vs. the untreated group and vs. the group treated with irbutinib alone.

[0063] Data reported in Figure 6a show that doubling the dose of irbutinib (50 mpk) administered to mice do not further decrease the volume of the tumors of the group of mice treated with the combination 5FU+irbutinib (compared to the group treated with 5FU+irbu 25 mpk). However, the treatment with the high dose of irbutinib has an anti-tumoral effect on its own: the statistical analysis reported in Figure 6b shows that, when compared to the untreated group, the reduction in the tumor volume obtained administering to the mice irbutinib 50 mpk is as significant as that obtained administering the combination 5FU+irbutinib 50 mpk.

[0064] These data show that the combined treatment with irbutinib and fluorouracil has a synergistic effect on the tumor volume reduction when low doses of irbutinib are administered together with chemotherapy to mice bearing drug-resistant xenografts and that an higher dosage of irbutinib has an anti-tumoral effect on its own. The graphs reported in Figure 7 show the results of the analysis performed on the tumoral tissues excised from the
mice at the end of the different treatments. To evaluate the proliferative index tissue sections were stained with antibodies against Ki67, a marker of proliferating cells. Percentage of Ki67-positive cells was quantified by Scanscope dedicated software upon digital acquisition of Ki67-stained, hematoxylin-eosin counter-stained slides (Figures 7a and b). Using another feature of the dedicated software also the percentage of necrotic area was calculated on the same slides (Figure 7c).

These data show that both, at low and high doses, neither Ibrutinib alone nor the combination Ibrutinib+5FU affect the proliferation of tumor cells whereas the combination increases significantly the extension of the necrotic area.

The graph in Figure 8a, represents the growth curve of tumors derived from HCT116 xenografted in CD1 mice after 28 days of treatment with vehicle alone, Ibrutinib (25mpk), 5FU (60mpk) and Ibrutinib (25mpk) + 5FU (60mpk). By the end of the treatment the average volume of the tumor masses formed by xenografted drug-sensitive HCT116 cells amounts to \( \approx 435 \text{mm}^3 \) for the group of untreated mice (vehicle), to \( \approx 347 \text{mm}^3 \) for the group treated with Ibrutinib (25mpk) alone, to \( \approx 226 \text{mm}^3 \) for the group treated with 5FU alone and to \( \approx 172 \text{mm}^3 \) for the group treated with the combination of Ibrutinib and 5FU. The difference in tumor size is not statistically significant between vehicle-treated and Ibrutinib-treated groups nor between 5FU-treated and 5FU+Ibrutinib-treated groups. Reduction in the tumor volume is in fact significant only when comparing the group of mice treated with 5FU \( \pm \) Ibrutinib vs the untreated (or Ibrutinib-treated) group.

Data plotted in the graph of Figure 8b represent the percentage of proliferating cells in the tumoral tissues excised from the mice at the end of the treatments shown above: 5FU treatment \( \pm \) Ibrutinib significantly reduces the percentage of proliferating cells compared to either vehicle or Ibrutinib alone.

The graph in Figure 9a, represents the growth curve of tumors derived from HCT116 xenografted in CD1 mice after 28 days of treatment with vehicle alone, Ibrutinib (50mpk), 5FU (60mpk) and Ibrutinib (50mpk) + 5FU (60mpk). By the end of the treatment the average volume of the tumor masses formed by xenografted drug-sensitive HCT116 cells amounts to \( \approx 435 \text{mm}^3 \) for the group of untreated mice (vehicle), to \( \approx 372 \text{mm}^3 \) for the group treated with Ibrutinib (50mpk) alone, to \( \approx 226 \text{mm}^3 \) for the group treated with 5FU alone and to \( \approx 223 \text{mm}^3 \) for the group treated with the combination of Ibrutinib and 5FU. The difference in tumor size is not statistically significant between vehicle-treated and Ibrutinib-treated groups nor between 5FU-treated and 5FU+Ibrutinib-treated groups. Reduction in the tumor volume is in fact significant only when comparing the group of mice treated with 5FU \( \pm \) Ibrutinib vs the untreated (or Ibrutinib-treated) group.

Data plotted in the graph of Figure 9b represent the percentage of proliferating cells in the tumoral tissues excised from the mice at the end of the treatments shown above: 5FU treatment \( \pm \) Ibrutinib significantly reduces the percentage of proliferating cells compared to either vehicle or Ibrutinib alone.

All together these data show that the growth-reducing and anti-proliferative effects of 5FU on sensitive xenografts are achieved independently from the addition of Ibrutinib, which by itself is ineffective in these kind of tumors.

Example 6. Treatment with Ibrutinib and fluorouracil: lower amounts of chemotherapeutic drug are sufficient

In Figure 10 is depicted the synergistic effect of singularly ineffective concentrations of 5FU and Ibrutinib in drug-resistant and -sensitive colon carcinoma cells. Figure 10a shows representative photographs of drug-resistant HCT116p53KO cells taken at 72 hours of incubation in presence of 200 \( \mu \text{M} \) 5FU, 20 \( \mu \text{M} \) Ibrutinib, 200 \( \mu \text{M} \) 5FU + 20 \( \mu \text{M} \) Ibrutinib: it is evident that only in the latter experimental condition few cells are still attached to the plate and that the vast majority of the cells are dead. Figure 10b shows representative photographs of sensitive HCT116 cells taken at 72 hours of incubation in presence of non-toxic concentrations of 5FU and Ibrutinib. When the two drugs are used singularly (10 \( \mu \text{M} \) 5FU and 50 \( \mu \text{M} \) Ibrutinib) no toxicity is evident, whereas when the two drugs are used in combination (10 \( \mu \text{M} \) 5FU + 50 \( \mu \text{M} \) Ibrutinib) all the cells are detached from the culture dish because are dead. The fourth picture, shown for comparison, is of a culture dish where HCT116 have been treated with the maximally effective concentration of 200 \( \mu \text{M} \).

These data clearly show that combining singularly ineffective concentrations of 5FU and Ibrutinib not only sensitize drug-resistant cells to chemotherapy but also allows to reduce the concentration of 5FU necessary to kill sensitive cells.

From the above description and the above-noted examples, the advantage attained by the product described and obtained according to the present invention are apparent.

Claims

1. Pharmaceutical kit for simultaneous, sequential and separate use of an effective dose of Ibrutinib and an effective dose of fluorouracil, in the treatment of colon and colorectal carcinomas.

2. Pharmaceutical kit according to claim 1, wherein the colon and colorectal carcinomas are drug-resistant.

3. Pharmaceutical kit according to anyone of claims 1 or 2, wherein the Ibrutinib is in the form of a pharmaceutically acceptable salt.
4. Pharmaceutical kit according to anyone of claims 1 to 3, wherein the effective dose of ibrutinib and the effective dose of fluorouracil are formulated as a pharmaceutical form selected from oral form, parenteral form and rectal form.

5. Pharmaceutical kit according to claim 4, wherein the pharmaceutical form is an oral form, preferably a tablet.

6. Pharmaceutical kit according to claim 4, wherein the pharmaceutical form comprises at least one pharmaceutical acceptable excipient.

7. Pharmaceutical kit according to anyone of claims 1 to 6, wherein the effective dose of ibrutinib is in the range of from 25 mg/day to 840 mg/day.

8. Pharmaceutical kit according to anyone of claims 1 to 7, wherein the effective dose of fluorouracil is in the range of from 400 mg/m² to 600 mg/m².

9. Pharmaceutical kit according to anyone of claims 1 to 8, comprising at least one container comprising the effective dose of ibrutinib and at least one container comprising the effective dose of fluorouracil, and an instruction leaflet.

10. Use of an effective dose of ibrutinib and an effective dose of fluorouracil, in the treatment of colon and colorectal carcinomas.

11. The use according to claim 10, wherein the colon and colorectal carcinomas are drug-resistant.

12. A method for the treatment colon and colorectal carcinomas, comprising the administration of and effective dose of ibrutinib and of an effective dose of fluorouracil.

13. The method according to claim 12, wherein the colon and colorectal carcinomas are drug-resistant.
Figure 2

[Diagram showing cell culture plates with varying concentrations of [ibrutinib] µM for HCT116, HCT116p53KO, DLD1, and SW480 cell lines.]
Figure 3

HCT116

% live cells

<table>
<thead>
<tr>
<th></th>
<th>0nM</th>
<th>100nM</th>
<th>500nM</th>
<th>1uM</th>
<th>5uM</th>
<th>10uM</th>
<th>20uM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibru</td>
<td>100</td>
<td>67,28</td>
<td>100,72</td>
<td>104,8</td>
<td>116,42</td>
<td>107,19</td>
<td>79,32</td>
</tr>
<tr>
<td>5FU+Ibru</td>
<td>29,48</td>
<td>19,58</td>
<td>19,53</td>
<td>24,95</td>
<td>36,34</td>
<td>14,4</td>
<td>17,24</td>
</tr>
</tbody>
</table>

HCT116p53KO

% live cells

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>100nM</th>
<th>500nM</th>
<th>1uM</th>
<th>5uM</th>
<th>10uM</th>
<th>20uM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibru</td>
<td>100</td>
<td>94,56</td>
<td>86,47</td>
<td>119,17</td>
<td>117,64</td>
<td>83,27</td>
<td>122,57</td>
</tr>
<tr>
<td>5FU+Ibru</td>
<td>98,1</td>
<td>67,86</td>
<td>47,56</td>
<td>44,26</td>
<td>34,36</td>
<td>39</td>
<td>31,03</td>
</tr>
</tbody>
</table>
Figure 4

HCT116p53KO

- Ibrutinib 1μM

- Cetuximab 10 μg/ml (chimeric mAb anti-EGFR)

- Panitumumab 75 μg/ml (humanized mAb anti-EGFR)

- Bevacizumab 25 μg/ml (anti-VEGF)

HCT116

- Ibrutinib 1μM

- Cetuximab 10 μg/ml (chimeric mAb anti-EGFR)
Figure 5

Figure 5a

- Vehicle
- 5FU 50mpk
- Ibrutinib 25 mpk
- Ibrutinib 25 mpk + 5FU 50mpk

Tumor Volume (mm³)

Days of treatment

Figure 5b

# ANOVA, Neményi-Damico-Wolfe-Dunn

Ibr25-5FU Vs. Ctrl, p = 0.012
Ibr25-5FU Vs. ibr25, p = 0.039
Figure 6

**Figure 6a**

- Vehicle
- 5FU 50mgk
- Ibrutinib 50 mgk
- Ibrutinib 50 mgk + 5FU 50mgk

**Figure 6b**

Tumor Volume

ANOVA, Namanyi-Damico-Wolfe-Dunn
Ibr/50+5FU Vs. Ctrl, p = 0.011
Ibr/50 Vs. Ctrl, p = 0.014
Figure 7

Figure 7a

Proliferative Index

% Ki67-positive cells

Ctrl 5FU ibr25 ibr25+5FU

Figure 7b

Proliferative Index

% of NEOT-positive cells

Ctrl 5FU ibr50 ibr50+5FU

Figure 7c

Necrosis

% necrotic area

Ctrl 5FU ibr25 ibr50 ibr25+5FU ibr50+5FU

ANOVA + LSD (Fisher) for pairwise comparison

*ibr25+5FU (ANOVA 0.011) †ibr50+5FU (ANOVA 0.004)

0.00 vs. Ctrl 0.009 vs. Ctrl

0.004 vs. 5FU 0.0003 vs. 5FU

0.003 vs. ibr25 0.03 vs. ibr50
Figure 8

Figure 8a

HCT116
ibru 25 mpk

Tumor Volume (mm³)

Days of treatment

Vehicle
5FU 60mpk
Ibrutinib 25 mpk
Ibrutinib 25 mpk + 5FU 60mpk

Figure 8b

Proliferative Index

Ki67 Labeling Index (%)

Control  5FU (60)  Ibrutinib (25)  Ibrutinib (25)+5FU
**Figure 9**

**Figure 9a**

**Figure 9b**

- **HCT116 Ibrutinib 50 mpk**
  - Vehicle
  - 5FU 50mpk
  - Ibrutinib 50 mpk
  - Ibrutinib 50 mpk + 5FU 50mpk

- **Proliferative Index**
  - Ki67 Labelling Index (%)
  - Control
  - 5FU (50)
  - Ibrutinib (50)
  - Ibrutinib (50)+5FU
## DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 2013/041014 A1 [LAVITRANO MARIALUISA [IT] ET AL] 14 February 2013 (2013-02-14) * paragraphs [0003], [0016], [0025], [0029], [0082], [0083], [0092], [0093]; claims 50,57-59, 63, 65, 72 *</td>
<td>1-13</td>
</tr>
</tbody>
</table>

### CLASSIFICATION OF THE APPLICATION (IPC)

<table>
<thead>
<tr>
<th></th>
<th>A61K31/513</th>
<th>A61K31/519</th>
<th>A61P35/00</th>
</tr>
</thead>
</table>

### TECHNICAL FIELD SEARCHED (IPC)

| A61K |

The present search report has been drawn up for all claims

**Place of search:** The Hague  
**Date of completion of the search:** 7 January 2014  
**Examiner:** Leherte, Chantal

**CATEGORY OF CITED DOCUMENTS**

- X: particularly relevant if taken alone
- Y: particularly relevant if combined with another document of the same category
- A: prior art on similar subject matter
- D: non-written disclosure
- T: technical background
- I: intermediate document
- E: earlier patent document, but published on, or after the filing date
- L: document cited for other reasons
- M: member of the same patent family, corresponding document
ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO. 07-01-2014

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDU file on 07-01-2014.

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US 2013041014 A1</td>
<td>14-02-2013</td>
<td>CA 2680589 A1</td>
<td>18-09-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2134374 A2</td>
<td>23-12-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2546651 A1</td>
<td>16-01-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2550976 A2</td>
<td>30-01-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2015021439 A</td>
<td>24-06-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20100015529 A</td>
<td>12-02-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010081704 A1</td>
<td>01-04-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2013041012 A1</td>
<td>14-02-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2013041013 A1</td>
<td>14-02-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2013041014 A1</td>
<td>14-02-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2009110624 A2</td>
<td>18-09-2008</td>
</tr>
</tbody>
</table>

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2008110624 A [0005] [0007]
- WO 2008039218 A [0008]
- WO 2010009342 A [0009]